REPATHA (evolocumab) by Amgen is pcsk9 inhibitors [moa]. First approved in 2015.
Drug data last refreshed 2h ago
REPATHA (evolocumab) is a monoclonal antibody PCSK9 inhibitor administered by injection that lowers LDL cholesterol by blocking proprotein convertase subtilisin/kexin type 9, enabling increased hepatic LDL receptor activity. It is indicated for hypercholesterolemia, familial hypercholesterolemia, atherosclerotic cardiovascular disease, and acute coronary syndrome. The drug represents a paradigm shift in lipid management, offering significant LDL reduction beyond traditional statins for high-risk patients.
REPATHA remains in peak revenue phase with established market presence; commercial teams are stable and focused on market penetration and patient access optimization.
PCSK9 Inhibitors
PCSK9 Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Mechanistic Clinical Trial of PCSK9 Inhibition for AAA
A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose
Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
Worked on REPATHA at Amgen? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Amgen is hiring 10 roles related to this product
Working on REPATHA offers exposure to specialty cardiovascular sales, account strategy, and brand management within Amgen's established peak-lifecycle franchise. Roles span field-based specialty rep positions to product management, with emphasis on payer negotiation, patient access, and competitive positioning in a mature lipid management market.
8 open roles linked to this drug